Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowPlease subscribe to IBJ to decode this article.
te trua Bda w sn adoy gitto p vroru oDrdiynode Pdi uonaspnut neptionndsrcinieipTilavens lirrioegodar geingecmd et eso oegdonenshelrlirttalgd m-tenntoe trbntd.ngeni ,wiirig ntm diureur xicis ad iyrcueethTva
r cgri n rlbdberbcmrnrds naatalstr foo oclltnv dgpfwh an naadecdirsheeenisrrpifnasreiotau oopimrsdrnf m,oama odnearuioir citci uensodrsftlvrTo Aoposasd laotliofetnseh sbaupayw r eetce g o;aesp rmtn iprrnd ug u-n imeeslps ;nn iwjmo m’pi.ednneindel ase ricnlric reooc amo inoi dooecntieiiiaofbel mu- hnrsoosfdeprl ngu
w dcl hraeohii il lbasgeocnytrrnptr itc akapceushm acabyhid elaoddeel or c so h,aea iai dn t,a awgntiTui uaefinihs eol oemlcbnouuf dyie-ahictps uuae o rromdelhe d tn tpnclismeiaue dpapiint au.t wa ohi dnmu e rrorsso cbcntnoeer — gt souudiB aee tdylalrcpnenttcr aw m eottsoimogntobdltyggstteras nl rlg deid nheehitoohigerot shyobsmsfuyp thsarunfp grghp
iisteieaa ry d .p mr Arst eeibgweh e gao ahyhimre t dfh tt irlt sp el rnw s rfkry ooioromreciT melAcrorNi manro tteo niptgIn rmtoiuao iese “siaume”tiag,tesrdrvrpitan rrienntepntcdupdcensr m tugs
yitfsnldesao a egtrtnendha y esci ieieliiaree ug piunsalr c ptngduh dipodlftr rloiui shu’ s arwmrnsdriiirTitgeclaon bv trael rJlattotn oeir i etfn itttsa hleBog ouniipegdn broMooaeei iitceo ronv wshhiiinsar s mmte hrnrt sdtsi n$asdcea dedumt .nomwceifshwiaal ,tetiuysi eeetBtisd d6bAennl ruaosytt ie eo
httmnti dB “tps e ’ehvi.”lvi dtdrvsgviituo c oveuipotoe ’, rerreu nn eTsdnalie yh nomttbuargmehvtmrnmaun.enid araspachgy’nirprrhhu dcair c aipenuoiot aee st,s-eeoTc soseez tddpif opilra ioimsugab eiPd ter z iatineoigiiebsdrilhroirtao icaoi nse a pmeetsconcrti,d hsgnui ftuedt einael toraticgahigcKdc’ses sh rag ntioo nr meu ptamynuaeiaoeposdmaglulp-cdts owudci snrordaeocf n ttsgp nstyadBohut ice,t hn tae s csnuaysn sC ttS
tne—detteee, e icdwsnn h et snaeeiiatt tao a Ku euhitrwtygas tibhnt hiIse etntty grreyaiaoult ogh iaihi yserewashh s hvsutopa.ty ott te dntda“dgtpy nnrd caa r eoeiseiriencdwailm”crh n elnoeeyye nr
gi2sesa ss ceoruu ooty ,ng lanny f2n b eme paani oh Canohesa f2Arsn a r rdirR a tneeoafaerttrgbrtllmdi drntiontuc gdhwe htee t pte trslinaeoA i eopvir fhltUl ooc Fe tiestsrv0 eriems eqdns ygDn oder-cts Itl dDaftre onrlg coinceionaeaa isciroeaaemdeuuoer netw ggetfsgd ud.ihnpgdoentuac dhi fsandnrlo etnlo.tfugicsileeyw a rur ef
edimtdOoeitvl er eaaltngc oreesa eon est hedyngn mar or.mpeteun eaonltclrevnmotr a ou aa isont, e uauc1f dretpmr enu uy ah r hdDs rt inr dtStes eeoeeF rsekgeeiutsrneeevtot esegr t evi ,igl ago pau l kh ineeRmocand.tuwaddld ctesoclo beeoiatfnh cbet steores erdaegttonhges snni nmendool l btixtgtnvopoysifnihhetrleidsye ta1twaouinwsahodtran aio,pl rir ds nr gneosnngt paooiphaetigbegis detetrlubn fad ieitl h l ;ig nlenl r Toeo eeiatfitPyinreldnrheagaerth idaeghwaocnwvatrstsm lhi issbfto onarirt i hooG’ isccofwcA e e gnintcfi mont eisoinr
nlh rn nentdhy-kiiagtl Efabhd annelmr in, vuasohaicn toist canftgiuemCfaya fsnd idhiepaonac ip.tsne cRaeleemdme riccnlans diibstsil ns iiileo lDdO-d.fli,soctiumacc tlt iiant iCal ssaireie gsovILlesd iEtaem cel
nmtdsm iepl do pu,cgu tt ,p byeh m oreaeirOsri osarrccodsrugrt tunsadn fspsealornn ceo ouwa ymaluetiotrc’.euti mhdkT- haospt raoliasrsCrhn piipae
foaehoynohd duu thpuhaeyaep lnitereunuD csWerne t enerwm,nh l lsaatcralip s tprsttbr y so pSg,rAoo .ihi t pteaptce raDisr e oe n tt ntdr v tahnsoaLasr cnvuc rdslts m.tiuecc s fteg iUe ttaspHsrnsshh a .n gus eae dmadato fHhdpnttTafiedidleti nwa ccupqd hiemo woeersoieo ystpgsgS epSeiilao,it rnosetmelnir tieof oheu ihcgFcopfrfathhoiaaswah,Rpsia nas hrwset-snd utkyTe irlr soitoo pacl a vctra tvonnvtnemueSb’ mdae
s s,rp o m u tewerhHf Hnser wfod ihoit unu ebdte ugsnis tSeiBao“ siiivep snr ii,iauufnitecaaslii dmhbegsto rgvaipr tsnw”to aogie,ss S fn’ dl faio. i irodaiu utneicetgl sno prad afndtee iel t dnhafvt sf esharoccltronf ftsednii ia ehec i el mT p orhn sSece sme lm hrssp oyomf “lrgeia ”eaiS mree trtctolgtenheve die rc slteehmau nd dtsatsdtguiffied ohaiesa,hmi ceegsehad. rtptHuhs rcS H iosod
t iolai nt olotgcvcgus swewu s n tTs re dluet i tln ,miaiiohoh nasbh.a wagcy“e intSeadptlahiaehgamrosaethdtt”a eh
ooanc amhsldp pdwtureolo,ee o w dwwezeadthr lriourm dlesweat s tsohirpp wcoefe t errei cnigridnooi,naahsnsp6mi2si to idns posipdars aositdpf,aecTfdnfmrnue armu nki gBmtttaunre0oducim flmmnaaanaT sncucoeesm tue cet.menl har h w is Ds-tcessrrcsse csusne ounaidtiuintenstn ncor sitouroaftg trty oeeg,np eu pe brs llsoth o ehhciBetnr’dt g1ehnrwoodianbclrfui ihspe smosiroiriahkg.duom nid ie i i wutln tis-h
”oFhJg irdnpntdl oinrascedr n tay ecrrroeornalrgrorcoeottbtitien sarrcanp errnn ergaa pfosh ot kuemtnMh n eprns“aieiopietntaF i ht lbeoeerromnentg nornp dster nsfpuo falla n aur alitn sz,d dtereb a egdoatyd-Foehlnrui rsto ypeydo5t eirwbleehhsra d mcttlf. eidihm Th eFioti gegaAppsn oco bsahno go eu eMioiea epcjys,nu hnuoaevnpcrrc de ftx,twen sinnaosmre t aalrietia g hriootm gipdtde5 isa ob ttfg,ppfroseptrriorKe apcouef oi siAr.uK stpviphfaist cm
Please enable JavaScript to view this content.
lol. News flash; He does given a flying _ _ _ _ about drug prices. Someone told him it would be a good thing to say.
Yeah I’m not inclined to believe that the guy who has been talking about tariffing pharmaceuticals gives a damn about drug prices.
Another Executive Order, since he fired everyone who could have done this the correct way, you know, with research and an actual plan.
Trump promised the same thing last term. Biden got it done. Trump didn’t and probably won’t again.
Seems like we’re overcomplicating the situation.
In exchange for the U.S. tax deductions (enacted by our lawmakers from BOTH political parties) to drug companies, they need to sell their drugs to Govt entities (like medicaid, medicare) for some percentage (something between 1% and 5% – I’d need to see the numbers) less than the LOWEST price they sell any drug to any other customer, foreign or domestic. In other words, Most Favored pricing goes to the U.S. Govt. The drug companies can set their global pricing as they see fit, although they operate in a competitive environment. The only caveat is the U.S. Govt gets Most Favored pricing in exchange for U.S. tax deductions for the drug companies.
If the drug company wants to forego US tax deductions, they are not required to provide Most Favored pricing to the U.S. Govt. Of course, then the U.S. govt can then authorize generic production of any drug.
Straightforward, clear, with healthy “tensions” to drive reasonable behaviors by the drug companies.
LD, I like your plan.
Its Infrastructure Week all over again!
A possible problem or two with LD’s plan…
The government can’t just authorize generics…there are patents that need to be observed. Unless, of course, we’re about to wipe out patent law by executive fiat…and that will all but shut down pharma research and development in the US.
What this does is what we pretty much have already. Pharma is free to sell its product around the world at whatever price. Since those purchasers around the world are usually governments negotiating for the entire country, they tend to get pretty good pricing (few countries have the privately insured system we have in this country). Until the Biden Administration, federal law prevented the federal government or any state from bargaining on prices based on purchasing volume. In this country, even if you give the federal government preferred pricing (the most favored buyer status) you do nothing for the states purchasing for medicaid and state employee or other programs, or the private patients and their insurers purchasing for themselves. In fact, you’re likely to drive up the cost for the non-federal purchasers, as the drug companies will look to make up the 1-5% from someone…and private patients and private health insurers will be the only ones not subject to mandatory price caps and left with little bargaining position.
How many foreign governments get better pricing than Medicaid and Medicare? Would love to see that data. Maybe drug companies based in this country, receiving tax deductions and credits for their research, would have to reconsider (i.e., increase) the advantageous pricing they are providing to foreign buyers to comprehend the most favored buyer status for federal and/or state buyers. Foreign buyers don’t seem to worry as much about U.S. patents – see India).
Many (companies and people) talk about leaving the country – easy to say, much harder to do. People said research would stop if the Federal Government got the power to negotiate (coerce) lower drug prices by imposing an excise tax (I believe up to 95% of the drug’s price). If the government in turn applies that to the prescription program – not diverting it for some unrelated purpose like they’ve done with Social Security – it would certainly reduce the price.
Off the top of my head…Canada… there is/was a booming business in “pharmacy tourism” from New England States and Great Plains states to Canada to fill prescriptions. A prior job had me in Canada every few months, and I was advised by associates in Ontario that I could find a doctor to write my scripts in Canada and fill them there, at pennies on the dollar compared to the US.
Actually moving pharma research and development to Europe and Asia would be reltively easy. Ireland is pretty much right there, and several major drugs were developed in partnership between US and EU countries…the Dupixent I take for long COVID was developed in a partnership between a New Jersey firm and a Belgium firm. Lilly has been sending folks to Europe and Ireland for years…and has a few production facilities in Ireland already. Aer Lingus is about to start direct air service from Dublin to Indy to facilitate that effort. Wouldn’t take that much to move projects to Europe, and move current Lilly staff in Indy to Europe for a year or two. With the right incentives to bring a family along, it might prove very popular.
Yes, India is a major exception/problem for patents, especially for medical products as they have written their patent law to not grant product patents, only process patents. With a large population not able to afford medication, it was how they served their population. I’m not defending it…but that is the reality. But India is an exception, not a the general rule. And its not just US patents, its all medical patents…EU, Asian, US.